Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 468-479

  Macy, Margaret E ^b   DeRyckere, Deborah ^b   Gore, Lia ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Acute leukemia; Combination therapy; Tyrosine kinase inhibitor; Vandetanib; Vascular endothelial growth factor

Indexed keywords

CD11B ANTIGEN; CD15 ANTIGEN; CD2 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; VANDETANIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; GYRASE INHIBITOR; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL SURFACE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ACUTE DISEASE; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN HL 60; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; GENETICS; HUMAN; IC 50; LEUKEMIA; METABOLISM; PATHOLOGY;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA; METHOTREXATE; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TOPOISOMERASE II INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862246554     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9572-6     Document Type: Article

References (65)

1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Be E (2009) Seer cancer statistics review, 1975-2006. National Cancer Institute, Bethesda
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106-130
3. Chessells JM (1998) Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol 102(2):423-438
4. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui CH (1996) Rearrangement of the mll gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 87(7):2870-2877
5. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta BM, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL (2010) Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia. Blood 115(7):1394-1405. doi:10.1182/blood-2009-05-218560
6. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B (2002) Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359(9321):1909-1915. doi:10.1016/S0140- 6736(02)08782-2
7. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME (2006) Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: children's oncology group study ccg-1941. J Clin Oncol 24(19):3150-3156. doi:10.1200/JCO.2005.04.5856
8. Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH (2005) Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 103(2):368-376. doi:10.1002/cncr.20743
9. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML (2010) Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study. J Clin Oncol 28(4):648-654. doi:10.1200/JCO.2009.22.2950
10. Ferrara N, Gerber HP, LeCouter J (2003) The biology of vegf and its receptors. Nat Med 9(6):669-676
11. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027. doi:10.1200/jco.2005.06.081
12. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094-1103. doi:10.1097/JTO.0b013e3181a97e31
13. Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121-3128
14. Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36(6):748-753
15. Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, Yao D, Tang Y, Chen X, Yang Z, Wang G, Li X, Zhao J, Ding H, Reed E, Li QQ (2004) Correlation of serum vegf levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 24(3b):1973-1979
16. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO (2002) Novel 4-anilinoquinazolines with c-7 basic side chains: design and structure activity relationship of a series of potent, orally active, vegf receptor tyrosine kinase inhibitors. J Med Chem 45 (6):1300-1312
17. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) Zd6474, an orally available inhibitor of kdr tyrosine kinase activity, efficiently blocks oncogenic ret kinases. Cancer Res 62 (24):7284-7290
18. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G (2003) Antitumor effects of zd6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9(4):1546-1556
19. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) Zd6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 (16):4645-4655
20. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of zd6474, an orally active inhibitor of vegf and egf receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16(8):1391-1397
21. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N (2006) A phase i dose-escalation study of zd6474 in japanese patients with solid, malignant tumors. J Thorac Oncol 1(9):1002-1009
22. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, Germonpre P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M (2009) Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27 (15):2523-2529. doi:10.1200/JCO.2008.18.6015
23. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE (2008) Randomized phase ii study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407-5415. doi:10.1200/JCO.2008. 17.3138
24. Johnson BE, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, Heymach JV (2005) Preliminary phase ii safety evaluation of zd6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with nsclc. J Clin Oncol (Meeting Abstracts) 23(16-suppl):7102
25. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28 (5):767-772. doi:10.1200/JCO.2009.23.6604
26. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J (2005) A multicenter phase ii trial of zd6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11 (9):3369-3376. doi:10.1158/1078-0432.CCR-04-1923
27. Nallapareddy S, Eckhardt S, O'Bryant C, Eppers S, Diab S, Kane M, Weekes C, Spratlin J, Messersmith W, Leong S (2010) A phase i study of gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies. Paper presented at the American Society of Clinical Oncology, Chicago, IL
28. Carlomagno F, Santoro M (2004) Identification of ret kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J Chemother 16(Suppl 4):49-51
29. Vidal M, Wells S, Ryan A, Cagan R (2005) Zd6474 suppresses oncogenic ret isoforms in a drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65(9):3538-3541. doi:10.1158/0008-5472.CAN-04-4561
30. Fragoso R, Elias AP, Dias S (2007) Autocrine vegf loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma 48 (3):481-488
31. Santos SC, Dias S (2004) Internal and external autocrine vegf/kdr loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103(10):3883-3889
32. Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI (2006) Correlation between high vascular endothelial growth factor-a serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: A report from children's oncology group study ccg-1962. Clin Cancer Res 12 (23):6978-6984
33. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94(11):3717-3721
34. de Bont ES, Neefjes VM, Rosati S, Vellenga E, Kamps WA (2002) New vessel formation and aberrant vegf/vegfr signaling in acute leukemia: Does it matter? Leuk Lymphoma 43(10):1901-1909
35. Gattei V, Celetti A, Cerrato A, Degan M, De Iuliis A, Rossi FM, Chiappetta G, Consales C, Improta S, Zagonel V, Aldinucci D, Agosti V, Santoro M, Vecchio G, Pinto A, Grieco M (1997) Expression of the ret receptor tyrosine kinase and gdnfr-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. Blood 89(8):2925-2937
36. Gattei V, Degan M, Aldinucci D, De Iuliis A, Rossi FM, Mazzocco FT, Rupolo M, Zagonel V, Pinto A (1998) Differential expression of the ret gene in human acute myeloid leukemia. Ann Hematol 77(5):207-210
37. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, Yoo NJ, Lee SH (2006) Kinase domain mutation of erbb family genes is uncommon in acute leukemias. Leuk Res 30(2):241-242
38. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR (2005) Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106(8):2841-2848. doi:10.1182/blood-2005-02-0488
39. Nishioka C, Ikezoe T, Takeshita A, Yang J, Tasaka T, Yang Y, Kuwayama Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H (2007) Zd6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel mek inhibitor, azd6244. Leukemia 21(6):1308-1310
40. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35:269-335
41. Gustafson DL, Bradshaw-Pierce EL, Merz AL, Zirrolli JA (2006) Tissue distribution and metabolism of the tyrosine kinase inhibitor zd6474 (zactima) in tumor-bearing nude mice following oral dosing. J Pharmacol Exp Ther 318(2):872-880
42. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, Katayama Y, Kimura G, Fujii N, Omoto E, Harada M, Orita K (1997) Two acute monocytic leukemia (aml-m5a) cell lines (molm-13 and molm-14) with interclonal phenotypic heterogeneity showing mll-af9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11(9):1469-1477
43. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I, Griffin C, Emanuel B, Finan J, Nowell P et al (1987) Growth factor requirements of childhood acute leukemia: establishment of gm-csf-dependent cell lines. Blood 70(1):192-199
44. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in aml: Analysis of 1, 612 patients entered into the mrc aml 10 trial. The medical research council adult and children's leukaemia working parties. Blood 92(7):2322-2333
45. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Zwaan CM, van den Heuvel-Eibrink MM (2009) Novel prognostic subgroups in childhood 11q23/mll-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114(12):2489-2496. doi:10.1182/blood-2009-04-215152
46. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ (2002) Mll translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30(1):41-47. doi:10.1038/ng765
47. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ (2004) Flt3 mutations in childhood acute lymphoblastic leukemia. Blood 103(9):3544-3546. doi:10.1182/blood-2003-07-2441
48. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA (2008) Mll-af9 and flt3 cooperation in acute myelogenous leukemia: Development of a model for rapid therapeutic assessment. Leukemia 22(1):66-77. doi:10.1038/sj. leu.2404951
49. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG (2006) Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with zd6474 (zactima), an inhibitor of vegfr and egfr tyrosine kinases. Mol Cancer Ther 5(7):1883-1894
50. Xu JM, Azzariti A, Colucci G, Paradiso A (2003) The effect of gefitinib (iressa, zd1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 52(6):442-448
51. Uittenbogaart CH, Nishanian PG, Anisman DJ, Erikson TK, Fahey JL (1986) Leukemia derived growth factors produced by human malignant t-lymphoid cell lines. Cancer Res 46(3):1219-1223
52. Bell JJ, Bhandoola A (2008) The earliest thymic progenitors for t cells possess myeloid lineage potential. Nature 452(7188):764-767. doi:10.1038/nature06840
53. Kang HK, Park JS, Kim SK, Choi BH, Pham TN, Zhu XW, Cho D, Nam JH, Kim YJ, Rhee JH, Chung IJ, Kim HJ, Lee JJ (2006) Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. Leuk Lymphoma 47(10):2224-2233
54. Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA (2010) A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer. doi:10.1002/cncr.25017
55. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT (2009) Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a doseand sequence-dependent manner. BJU Int 103(12):1729-1737. doi:10.1111/j.1464-410X.2009.08367.x
56. Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG (2007) Investigation of two dosing schedules of vandetanib (zd6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 13(21):6450-6458. doi:10.1158/1078-0432.CCR-07-1094
57. Dias S, Choy M, Alitalo K, Rafii S (2002) Vascular endothelial growth factor (vegf)-c signaling through flt-4 (vegfr-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99(6):2179-2184
58. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Autocrine stimulation of vegfr-2 activates human leukemic cell growth and migration. J Clin Invest 106(4):511-521
59. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabecadas J, Dias S (2006) Vegfr-1 (flt-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 107(4):1608-1616
60. Hussong JW, Rodgers GM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95(1):309-313
61. Shen HL, Xu W, Wu ZY, Zhou LL, Qin RJ, Tang HR (2007) Vector-based rnai approach to isoform-specific downregulation of vascular endothelial growth factor (vegf)165 expression in human leukemia cells. Leuk Res 31(4):515-521
62. Mi Y, Lou L (2007) Zd6474 reverses multidrug resistance by directly inhibiting the function of p-glycoprotein. Br J Cancer 97 (7):934-940. doi:10.1038/sj.bjc.6603985
63. Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, Yang AK, To KK, Fu LW (2009) Vandetanib (zactima, zd6474) antagonizes abcc1- and abcg2-mediated multidrug resistance by inhibition of their transport function. PLoS One 4(4):e5172. doi:10.1371/journal.pone.0005172
64. Treichel RS, Bunuan M, Hahn N, Wee K (2004) Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (nk) cells. Int J Cancer 108(1):78-85. doi:10.1002/ijc.11555
65. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F (2005) Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16(Suppl 4):iv61-iv68. doi:10.1093/annonc/mdi910